Integer Holdings Corporation reports news as a medical device contract development and manufacturing organization serving cardio and vascular, neuromodulation, and cardiac rhythm management markets. Company updates commonly cover sales trends, organic growth, product-line performance, adjusted earnings measures, debt and leverage, and outlook commentary tied to customer programs and new product activity.
Integer news also includes governance and capital-allocation developments, including board composition, shareholder engagement, share repurchase authorization, investor conference participation, and broader strategy updates. The company’s public identity includes the Greatbatch Medical and Lake Region Medical brands and engineering and manufacturing work for medical device customers.
Integer Holdings Corporation (NYSE:ITGR) announced its participation in the Piper Sandler 34th Annual Healthcare Conference from November 29 to December 1, 2022. CEO Joe Dziedzic will present on November 30, 2022, at 8:10 a.m. ET. The presentation, including a Q&A session, will be available via live webcast on Integer's website, with replays archived for 30 days. Integer is a leading medical device outsource manufacturer serving various markets, including cardiac and orthopedics, and develops specialized batteries for high-end applications.
Integer Holdings Corporation (NYSE:ITGR) reported a 12% increase in sales to $343 million for Q3 2022, but GAAP net income fell 27% to $16 million. Non-GAAP adjusted net income also declined by 9%. Debt increased by $111 million to $939 million, driven by the Aran Biomedical acquisition, leading to a leverage ratio of 3.8 times adjusted EBITDA. Despite challenges in supply chain performance, management anticipates 7% to 9% growth in revenue for 2023, with margin expansion expected. Organic sales growth outlook for 2022 is 4% to 6%.
Integer Holdings Corporation (NYSE: ITGR) provided a revised 2022 outlook amidst ongoing supply chain challenges and strong customer demand. Q3 sales were negatively impacted by $15 million due to supplier issues, leading to an expected $25 million decrease in full-year operating income. Despite higher manufacturing costs, Integer is reducing SG&A expenses by $8 million annually. The 2023 sales outlook remains optimistic at 7-9% growth, driven by strong demand and a robust backlog.
Integer Holdings Corporation (NYSE:ITGR) reported a 12% increase in sales for Q2 2022, totaling $350 million, aided by recent acquisitions. However, GAAP net income decreased by 29% to $21 million, and GAAP diluted EPS dropped to $0.62, down $0.27 per share. The company raised its full-year sales outlook to 12%-14% growth, driven by demand in electrophysiology and structural heart markets. However, total debt rose to $947 million, increasing the leverage ratio to 3.9 times adjusted EBITDA.
Integer Holdings Corporation (NYSE:ITGR) plans to release its financial and operational results for Q2 2022 on July 28, 2022, at 7 a.m. CT / 8 a.m. ET. Following the release, management will host a webcast at 8 a.m. CT / 9 a.m. ET to discuss the results and any other forward-looking information. Key details include domestic and international dial-in numbers and the registration link for the webcast.
Integer Holdings Corporation (NYSE:ITGR) reported a 7% increase in sales to $311 million for Q1 2022, despite facing challenges from COVID-19 absenteeism and supply chain constraints. GAAP net income fell by 47% to $11 million. The company completed the acquisition of Aran Biomedical, enhancing its product offerings in the cardiovascular market, expected to add $90 million in annual sales. For 2022, Integer anticipates 11% to 13% sales growth with continued efforts to improve gross margins and address labor challenges.
Integer Holdings Corporation (NYSE: ITGR) announced the acquisition of Connemara Biomedical Holdings for €120 million, with an additional €10 million contingent on 2022 revenue growth. This acquisition enhances Integer's capabilities in implantable medical devices, particularly in the cardiovascular sector, where Aran Biomedical's expertise in biomaterials will complement Integer's existing offerings. Aran Biomedical generated $17 million in sales in 2021, nearly doubling from the previous year, and the acquisition is immediately accretive to Integer’s sales growth and profit margins.
Integer Holdings Corporation (NYSE:ITGR) will announce its first quarter 2022 financial results on April 28, 2022, at 7 a.m. CT. A conference call will follow at 8 a.m. CT, featuring management's discussion on the results and potential forward-looking insights. Investors can join the call domestically at (888) 330-3567 or internationally at (646) 960-0842, using Conference ID 9252310. The event will also be available via webcast. Integer is a leading medical device manufacturer, serving various markets and providing high-quality technologies.
Integer Holdings Corporation (NYSE:ITGR) announced that CEO Joe Dziedzic and CFO Jason Garland will participate in a virtual fireside chat at the KeyBanc Life Sciences & MedTech Investor Forum. This event is scheduled for March 23, 2022, at 3:45 PM ET. A live webcast will be available on the company's website, with a replay offered post-event. Integer is a leading medical device outsource manufacturer, serving various markets including cardiac and orthopedics, and develops specialized batteries for niche applications.
Integer Holdings Corporation (NYSE:ITGR) announced the retirement of Bill R. Sanford as Chair of the Board, effective after the 2022 annual meeting on May 18, 2022. Pamela G. Bailey, a long-standing board member since 2002, will succeed him. Sanford has served 14 years as Chair and contributed to the company’s strategic growth. Bailey's extensive experience, including her tenure as President and CEO of AdvaMed, is expected to ensure a seamless leadership transition. Integer is a leading medical device outsource manufacturer serving various markets.